抗肿瘤抗体偶联药物靶向递送的研究进展

吴林霏; 胡珊珊; 黄嘉敏; 沈红璋; 张筱凤*

引用本文:	吴林霏,胡珊珊,黄嘉敏,沈红璋,张筱凤*.抗肿瘤抗体偶联药物靶向递送的研究进展[J].中国现代应用药学,2024,41(9):1281-1286.
	WU Linfei,HU Shanshan,HUANG Jiamin,SHEN Hongzhang,ZHANG Xiaofeng*.Advances in the Targeted Delivery of Antibody Drug Conjugates[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(9):1281-1286.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 297次下载 325次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
抗肿瘤抗体偶联药物靶向递送的研究进展
吴林霏¹, 胡珊珊¹, 黄嘉敏¹, 沈红璋², 张筱凤*²
1.浙江中医药大学第四临床医学院，杭州 310005;2.杭州市第一人民医院消化内科，杭州 310005

摘要:

抗体与抗原结合的靶向递送是一种精准的递药方式，由于其高特异性和亲和力被视为理想的靶向递药方式之一，这为成功解决抗肿瘤治疗中化疗药物选择性差的问题开辟了新的道路。当前，利用单克隆抗体与靶抗原结合的抗体偶联药物(antibody drug conjugates，ADCs)研究成为分子靶向治疗的研究热点，本文就ADCs靶向递送的作用机制、靶向策略和靶向递送进展进行综述，以期为临床开发新的ADCs提供参考。

关键词: 靶向递送抗体偶联药物恶性肿瘤治疗进展

DOI：10.13748/j.cnki.issn1007-7693.20230840

分类号:

基金项目:国家自然科学基金项目(82304628)；浙江省自然科学基金项目(LQ23H160047)；浙江省医药卫生科技计划项目(WKJ-ZJ-2136)

Advances in the Targeted Delivery of Antibody Drug Conjugates

WU Linfei¹, HU Shanshan¹, HUANG Jiamin¹, SHEN Hongzhang², ZHANG Xiaofeng*²

1.The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310005, China;2.Department of Gastroenterology, Hangzhou First People Hospital, Hangzhou 310005, China

Abstract:

Targeted delivery of antibody bound to antigen is a precise drug delivery mode. It is regarded as one of the ideal targeted drug delivery modes due to its high specificity and affinity, which opens up a new way to successfully solve the problem of poor selectivity of chemotherapy drugs in antitumor therapy. Currently, the research on antibody drug conjugates(ADCs) that bind monoclonal antibodies to target antigens has become a research hotspot of molecular targeted therapy. This paper reviews the mechanism of action, targeting strategies and progress in the targeted delivery of ADCs, in order to provide reference for the clinical development of new ADCs.

Key words: targeted delivery antibody drug conjugates malignant tumor treatment progress